Institutional Ownership
Ac Immune SA
CUSIP H00263105SHSACIUQ1 2026
13D / 13G Filings
18
Schedule 13D/13G on record
Beneficial Filers
7
Distinct reporting persons
Largest Stake
26.7%
Max % of class reported
Institutional Holders
46
13F filers (latest quarter)
Beneficial Owners — Schedule 13D / 13G
18 filings · latest Dec 13, 2024
| # | Filed | Reporting Person | Form | % of Class | Shares | Filing |
|---|---|---|---|---|---|---|
| 1 | Dec 13, 2024 | Affiris AG In Liqu | 13G/A | 6.5% | 6.43M | SEC |
| 2 | Nov 14, 2024 | Biotechnology Value Fund L P | 13G/A | 10.4% | 10.29M | SEC |
| 3 | Feb 9, 2024 | Affiris AG In Liqu | 13G/A | 6.7% | 6.58M | SEC |
| 4 | Dec 19, 2023 | Biotechnology Value Fund L P | 13G/A | 7.7% | 7.65M | SEC |
| 5 | Feb 14, 2023 | Affiris AG In Liqu | 13G/A | 8.1% | 6.72M | SEC |
| 6 | Feb 14, 2023 | Biotechnology Value Fund L P | 13G/A | 4.8% | 3.98M | SEC |
| 7 | Feb 10, 2023 | Dievini Hopp Biotech Holding Gmbh & Co Kg | 13G/A | 19.5% | 16.32M | SEC |
| 8 | Jan 27, 2023 | Eli Lilly & Co | 13G/A | 4.3% | 3.62M | SEC |
| 9 | Feb 14, 2022 | Ecor1 Capital, LLC | 13G/A | 0.9% | 749.6K | SEC |
| 10 | Feb 14, 2022 | Biotechnology Value Fund L P | 13G/A | 5.0% | 3.65M | SEC |
8 more beneficial-ownership filings on Premium
See the full Schedule 13D/13G history for Ac Immune SA.
Unlock full historyTop Institutional Holders (13F)
Largest reported positions · latest quarter
| # | Fund | Shares | Value |
|---|---|---|---|
| 1 | Bvf Inc/Il | 19.82M | $54.51M |
| 2 | Wells Fargo & Company/Mn | 1.00M | $2.76M |
| 3 | Millennium Management LLC | 792.7K | $2.18M |
| 4 | Renaissance Technologies LLC | 624.4K | $1.72M |
| 5 | Blackrock, Inc. | 524.3K | $1.44M |
| 6 | Arrowstreet Capital, Limited Partnership | 405.7K | $1.12M |
| 7 | Dimensional Fund Advisors LP | 390.2K | $1.07M |
| 8 | Northern Trust Corp | 278.5K | $765.9K |
| 9 | Citadel Advisors LLC | 267.2K | $734.9K |
| 10 | Marshall Wace, LLP | 131.5K | $361.5K |